IL-17 vs IL-23 sequencing in psoriatic arthritis
Real-world sequencing data is settling the IL-17 vs IL-23 question in psoriatic arthritis with a more nuanced answer than psoriasis alone implied.
Psoriatic arthritis presents both skin and joint involvement, and the IL-17 vs IL-23 sequencing question plays out differently than in psoriasis-only patients. Real-world data now shows IL-17 inhibitors retaining a stronger position in axial PsA, while IL-23 inhibitors show preferential response in peripheral PsA with prominent skin involvement. The implication is that PsA is not psoriasis with joint involvement; it is a different prescribing decision.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- ExplainedWhat is Sjogren disease?